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The deposition of chemical modifications into RNA is a crucial regulator of temporal and 15 
spatial accurate gene expression programs during development. Accordingly, altered RNA 16 
modification patterns are widely linked to developmental diseases. Recently, the 17 
dysregulation of RNA modification pathways also emerged as a contributor to cancer. By 18 
modulating cell survival, differentiation, migration, and resistance, RNA modifications add a 19 
novel regulatory layer of complexity to most aspects of tumourigenesis. 20 
21 
 2
Post-transcriptional RNA modifications  22 
Currently, over 170 RNA modifications are known, and most RNA species contain one or 23 
multiple distinct chemical modifications 1. Determining the function of these modifications in 24 
RNA metabolism requires their reliable detection at single-nucleotide resolution. Only a 25 
handful of modifications can be mapped at high resolution using high throughput (HTP) 26 
sequencing technologies 2. However, these newly developed technics have revealed that RNA 27 
modifications modulate most steps of gene expression from RNA transcription to protein 28 
translation. Here, we will focus on recently discovered regulatory functions of RNA 29 
modifications and discuss their emerging roles in regulating cell fate in normal tissues and 30 
cancer.  31 
 32 
Protein synthesis occurs at the ribosome and involves the translation of the messenger RNA 33 
(mRNA) into amino-acids via transfer RNAs (tRNA). Ribosomal RNA (rRNA) is the most 34 
abundant type of RNA in a cell. Around 130 individual rRNA modifications have recently 35 
been visualized in the three-dimensional structure of the human ribosome 3. The most 36 
abundant rRNA modifications in eukaryotes are 2′-O-methylation of the ribose and the 37 
isomerisation of uridine to pseudouridine (Ψ) 4. Most rRNA modifications occur in or close 38 
to functionally important sites and can facilitate efficient and accurate protein synthesis when 39 
they occur for instance at the peptidyltransferase center and the decoding site 3,4. 40 
 41 
Tens of millions of tRNA transcripts occur in a human cell, and tRNA is the most modified 42 
RNA in a cell 5. The modifications are highly diverse, and their functions depend on the 43 
location within a tRNA and its chemical nature (Figure 1a). The most common tRNA 44 
molecules consist of 76 nucleotides 6. A human tRNA contains between 11 to 13 different 45 
modifications 7. Accordingly, a large number of enzymes are involved in the site-specific 46 
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deposition of the modifications (Figure 1a). The modifications range from simple 47 
methylation or isomerization events, such as m5C, m1A, Ψ, 5-methyluridine (m5U), 1- and 48 
1/7-methylguanosine (m1G, m7G), and inosine, to complex multistep chemical modifications, 49 
such as N6-threonylcarbamoyladenosine (t6A) and 5-methoxycarbonylmethyl-2-thiouridine 50 
(mcm5s2U) 5.  51 
 52 
The most abundant internal modification in mRNA (and also long non-coding RNA) is N6-53 
methyladenosine (m6A) 8-11. Around 0.1 to 0.4% of all mRNA adenines are methylated, 54 
representing approximately 3-5 modifications per mRNA 11-13. Other rarer modifications 55 
within eukaryotic mRNA include N1-methyladenosine (m1A), N6-2’O-dimethyladenosine 56 
(m6Am), 5-methycytosine (m
5C), 5-hydroxymethylcytosine (hm5C), and pseudouridine (Ψ) 57 
(Figure 1b) 14-21. Some of these modifications are generated by stand-alone enzymes 22, 58 
others are installed by multi-protein writer complexes and accessory subunits (Figure 1b) 23.  59 
 60 
RNA modifications modulate gene expression programs  61 
The first step of gene expression is the transcription of DNA molecules into mRNA. The 62 
deposition of m6A into nascent pre-mRNA is carried out in the nucleus by a multicomponent 63 
methyltransferase complex 24,25. The multi-protein writer complex installing m6A consists of 64 
the Methyltransferase Like catalytic subunits (METTL3, METTL14), and many other 65 
accessory subunits 23. Gene-specific transcription factors and chromatin modifying enzymes 66 
can further modulate the deposition of m6A into nascent RNA by repelling or recruiting the 67 
m6A writer complex 26-28.  68 
 69 
Two demethylases, Fat Mass and Obesity-associated protein (FTO) and AlkB Homolog 5 70 
(ALKBH5) act as erasers of the m6A modification (Figure 2a) 29,30. Several reader proteins 71 
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selectively bind m6A containing mRNAs. For instance, binding of YTH N6-Methyladenosine 72 
RNA Binding Protein 2 (YTHDF2) targets the transcripts for degradation 31-34. Recruitment 73 
of YTHDF1/3 enhances translation (Figure 2a)  35,36. The deposition of m6A and other 74 
additional mRNA modifications contribute to most aspects of RNA metabolism such as 75 
transcript stability, pre-mRNA splicing, polyadenylation, mRNA export, and translation 76 
23,37,38. 77 
 78 
The second major step in gene expression is mRNA translation. Multiple aspects of protein 79 
synthesis are differently regulated among somatic cells and thereby contribute to cell identity 80 
and function within tissues 39. Eukaryotic cells rely on the tight control of mRNA translation 81 
to quickly respond to a changing micro-environment, including nutrient deprivation and 82 
stress, development and differentiation, and cancer 39-41. All three main types of RNAs 83 
involved in translation (mRNA, tRNA and rRNA) are highly modified in mammals, and their 84 
interaction with the respective modifying enzymes often results in qualitative and quantitative 85 
changes of protein synthesis 4,5,23. 86 
 87 
tRNA modifications modulating mRNA translation  88 
Transfer RNAs have multiple and versatile functions in regulating gene expression. To 89 
decode only 20 amino acids, the human genome encodes at least 610 tRNAs that are often 90 
tissue-specifically expressed 42-44. All tRNAs carry modifications, but the extent of 91 
modifications in individual tRNAs varies and mitochondrial tRNAs are generally less 92 
modified, containing on average of five modifications per molecule 5. The diversity of 93 
modifications together with their highly similar L‐shaped fold gives tRNAs the propensity to 94 
interact with a large number of RNAs and proteins during translation to modulate protein 95 
synthesis rates 45. 96 
 5
 97 
RNA modifications can occur along the whole L-shape of the tRNA, yet they are the most 98 
diverse at the wobble position, where they often optimize codon usage during gene-specific 99 
translation (Figure 1a; C34 pink) 46-48. For example, uridines in position 34 of the wobble 100 
base of tRNAUUU, tRNAUUC, tRNAUUG and tRNAUCU can contain a 5-carbamoylmethyl 101 
(ncm5) or 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2) side-chains. This requires the 102 
successive activities of the conserved acetyltransferase six-subunit Elongator complex, the 103 
methyltransferase ALKBH8, and the thiouridylase CTU1/CTU2, together with the URM 104 
pathway (Ubiquitin-Related Modifier pathway) (Figure 2b) 49,50. The wobble modification 105 
enhances base-pairing and protein translation of mRNAs enriched for the corresponding 106 
codons 49-51. Loss of the modification leads to codon-specific translation pausing of the 107 
ribosomes 52,53.  108 
 109 
Cytosine-5 methylation (m5C) occurs in the anti-codon loop and the variable arm of tRNAs 110 
(Figure 1a) 54. The methyltransferase NSUN3 is required for the formation of m5C at the 111 
wobble position in mitochondrial tRNA for start methionine (tRNAMet) 55,56. NSUN3-112 
dependent deposition of m5C is required to initiate the subsequent biogenesis of 5-113 
formylcytidine (f5C), which is mediated by the RNA dioxygenase AlkB Homolog 1 114 
(ALKBH1) 55-58. Consequently, loss of these modifications due to deletion of NSUN3 115 
inhibits mitochondrial protein translation and impairs mitochondrial functions.  Other 116 
modifications that occur in the anticodon loop, but not at the wobble position, such as t6A at 117 
position 37 and m5C at position 38 modulate translation elongation rates and fidelity 118 
respectively 59,60.  119 
 120 
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Modifications outside the anticodon loop are often implicated in tRNA processing and 121 
cleavage. Deposition of m5C and Ψ modulates the biogenesis of tRNA-derived small non-122 
coding RNA fragments (tRFs) 61-63. Loss of NSUN2-mediated methylation at the variable 123 
loop increases the affinity to the endonuclease angiogenin, and thereby promotes cleavage of 124 
tRNAs into tRFs, which then inhibit global protein synthesis (Figure 2c) 54,64. The deposition 125 
of Ψ by PUS7 also influences the biogenesis of tRFs; yet interestingly, loss of PUS7 leads to 126 
increased protein biosynthesis 62. Deposition of Queuosine (Q) at the wobble anticodon 127 
position of tRNAs protects against ribonuclease cleavage 65, and Q-tRNA levels promote 128 
DNMT2-mediated methylation 66. Together, m5C and Q control translational speed of Q-129 
decoded codons as well as at near-cognate codons 66. Loss of DNMT2-mediated methylation 130 
at the anti-codon loop (C38) causes tRNA-specific fragmentation and codon-specific 131 
mistranslation 60. Depletion of queuine, the precursor for Q, which is provided through the 132 
diet and gut microbiota, results in unfolded proteins triggering the endoplasmic reticulum 133 
stress response 66.  134 
 135 
In summary, in response to environmental cues, tRNA modifications can act as a rheostat of 136 
protein synthesis rates via at least two mechanisms. First, modifications outside the anticodon 137 
loop often modulate the rate of de novo protein synthesis. Second, modifications within the 138 
anticodon loop can determine the translation speed of codon-specific genes. Because wobble 139 
base modifications usually affect gene-specific translation, they have the potential to directly 140 
modulate distinct cellular functions such as survival, growth or differentiation.  141 
 142 
The regulatory potential of RNA modifications in cancer  143 
Due to their ability to modulate many aspects of RNA metabolism and influence protein 144 
synthesis rates, several RNA modifications emerged as important regulators in cancer 51,67,68. 145 
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Similar to normal tissues, also a tumour contains functionally and phenotypically different 146 
cell populations. Tumour heterogeneity is the consequence of genetic change, environmental 147 
differences, and reversible changes in cellular properties 69. The heterogenous cell 148 
populations are not equally tumourigenic. Some cancer cells are more differentiated with a 149 
limited tumorigenic potential. Others, potentially even rare tumour populations, exhibit stem 150 
cell-like features that drive tumourigenesis, long-term survival, and therapy resistance 70. 151 
While RNA modifying-enzymes are generally not considered to be cancer driver genes, they 152 
have been functionally linked to sustain cell survival, proliferation, growth or differentiation 153 
of tumour-initiating cells. Abnormal expression of RNA modifying enzymes can reduce the 154 
tumour cell’s sensitivity towards differentiation cues (m6A, m5C) or sustain the expression of 155 
specific genes required for proliferation, invasion and resistance to anti-cancer drugs 156 
(mcm5s2U, m6A, m5C). 157 
 158 
RNA modifications regulating the fate of tumour-initiating cells  159 
Members of the mcm5s2U writer complex are upregulated in melanoma as well as colon and 160 
breast cancer 71-73. ELP3, the catalytic subunit of the Elongator complex, is required for Wnt-161 
driven intestinal tumour initiation 72. Deletion of ELP3 in Lgr5+ tumour initiating cells delays 162 
tumor growth, yet the number of Lgr5+ cells remains unchanged 72,74. Thus, the correct 163 
formation of mcm5s2U promotes the tumourigenic potential of specific cell populations 72. A 164 
cell type-specific function of ELP3 can be explained by the codon-specific effect of mcm5s2U 165 
on translation. For instance, in colon cancer cells, ELP3 promotes translation SOX9, a down-166 
stream target of Wnt/β-catenin signaling 72,75. In breast cancer, ELP3 enhances translation of 167 
the DEK proto-oncogene, whose mRNA is enriched for mcm5s2U sensitive codons 71. 168 
 169 
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A cell type-specific functional requirement of mcm5s2U is also exemplified in development. 170 
While Elongator is required for the brain, it is dispensable for the formation of intestine and 171 
mammary glands 71,72,76-78. Loss of ELP3 in the developing brain leads to microcephaly. 172 
Ribosome profiling in the mutant forebrain revealed enhanced pausing at putative mcm5s2U 173 
sites. These codon-specific translation defects may cause an accumulation of unfolded or 174 
misfolded proteins and thereby explain the activation of the endoplasmic reticulum (ER) 175 
stress response, leading to the activation of the Unfolded Protein Response (UPR) pathway 76. 176 
In contrast, melanoma and breast cancer cells fail to activate the UPR pathway, again 177 
indicating that mcm5s2U modification exerts cell context-specific functions 71,79.  178 
 179 
The deposition of m5C by NSUN2 is also required for normal development and implicated in 180 
cancer 64,80-84. Loss of the NSUN2 gene causes growth retardation and neuro-developmental 181 
deficits in human and mice 54,80-82. In cutaneous tumours, NSUN2 is absent in tumour-182 
initiating cells but highly expressed in committed progenitor populations. Accordingly, 183 
deletion of NSUN2 increases the number of tumour-initiating cells (Figure 3) 64. As 184 
described for some tissue stem cells, also tumour-initiating cells of skin tumours are 185 
functionally maintained by low protein synthesis rates, which is at least in part maintained by 186 
tRFs in the absence of NSUN2 64,85-87. Thus, similar to the cellular response to stress or 187 
injury, in which global protein synthesis is commonly reduced 88, tumour-initiating cells may 188 
also require low translation rates to alleviate cellular damage and increase longevity and 189 
survival rate.   190 
 191 
The correct deposition of m6A into mRNA is essential for embryo development and cell 192 
differentiation due to its role in governing the stability of key regulatory transcripts 23. 193 
Complete absence of m6A due to deletion of METTL3 is early embryonic lethal due to the 194 
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extended transcript lifetime of key pluripotency regulators (e.g.  Nanog, Sox2, and Klf4) and 195 
the inability to start differentiation programs (Figure 2a) 89,90. Thus, the deposition of m6A 196 
affects the stability of distinct groups of transcripts, for instance pluripotency factors, 197 
allowing their synchronized regulation. This coordination of RNA metabolism then allows 198 
the cell to transit through specific cell states, such as self-renewal, proliferation or 199 
differentiation, in response to cellular signaling and environmental cues. These 200 
environmental cues may include growth factors, cytokines, or external stress factors (e.g. 201 
hypoxia, oxidative stress, or injury). Such a mechanism allowing the fast adaptation to 202 
changing micro-environments is also required in tumours (Figure 3).  203 
 204 
Increased levels of m5C and m6A in RNA was first reported in circulating tumour cells of 205 
lung cancer patients by mass spectrometry 91. However, several studies then showed that m6A 206 
de-methylation promotes proliferation and tumourigenesis in different types of cancer. 207 
Hypoxia-induced up-regulation of ALKBH5 in breast cancer cells decreased m6A and 208 
enhances mammosphere formation 92. ALKBH5 is also highly expressed in glioblastoma and 209 
sustains the proliferation of patient-derived glioblastoma cells 93.  210 
 211 
The m6A de-methylase FTO is highly expressed in patients with acute myeloid leukemia 212 
(AML) 94. FTO enhances leukemic oncogene-mediated cell transformation and 213 
leukemogenesis by promoting cell proliferation and survival and inhibiting all-trans-retinoic 214 
acid (ATRA)-induced AML cell differentiation 94. Knockdown of METTL3 or METTL14 215 
also promotes tumourigenesis of primary human glioblastoma cells in vitro and in vivo, an 216 
effect that was reverted by overexpression of METTL3 or inhibition of FTO 95. Similarly, R-217 
2-hydroxyglutarate (R-2HG), an oncometabolite that inhibits FTO, also exerts an anti-218 
leukemic activity in vitro and in vivo 96. Treatment with R-2HG increased m6A leading to 219 
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degradation of Myc/Cebpa transcripts and suppression of the relevant down-stream pathways 220 
96. Finally, 70% of endometrial tumours exhibit m6A reduction, either attributed to METTL14 221 
mutation or METTL3 downregulation 97. Low levels of m6A enhances proliferation and 222 
tumorigenesis of endometrial cancer cells, through AKT signaling pathway 97.  223 
 224 
Unexpectedly, the m6A methyltransferase METTL3 is also more abundant in AML cells 225 
when compared to healthy CD34-positive stem and progenitor hematopoietic cells 98, and is 226 
essential for the growth of acute myeloid leukaemia cells 28,98. Downregulation of METTL3 227 
or METTL14 causes cell cycle arrest and differentiation of leukaemic cells through 228 
transcriptional repression of distinct sets of transcripts, such as genes containing a CAATT-229 
box binding protein at the transcription start site in the absence of METTL3 and Myb and 230 
Myc in the absence of METTL14 28,99. Together, these studies indicate that elevated levels of 231 
m6A is advantageous for the maintenance of an undifferentiated cell state in leukemia. 232 
Similarly, METTL3 promotes growth, survival, and invasion of human lung cancer cells 100. 233 
Yet in this study, METTL3 promoted translation of certain mRNAs (e.g. Egfr and Taz) 234 
through association with ribosomes in the cytoplasm, this function was independent of its 235 
catalytic activity and m6A readers 100. The m6A reader Insulin-like growth factor 2 mRNA-236 
binding proteins (IGF2BP) also promotes mRNA stability and translation of its target 237 
mRNAs, for example Myc (Figure 2a)101. 238 
 239 
Together, these studies reveal that aberrant methylation and de-methylation of mRNA 240 
influences tumour initiation and growth. The precise underlying mechanisms how both m6A 241 
methylases and de-methylases can promote tumourigenesis remain unclear. However, 242 
methylation and de-methylation events occur on distinct and often cell-state specific key 243 
regulatory transcripts at gene-specific regions 102. In addition, these sets of transcripts are 244 
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likely to differ in stem cells and undifferentiated or committed progenitors. Thus, depending 245 
on the cell of origin of the respective tumour and the identity of the distinct driver mutations, 246 
the degradation or stabilization of distinct sets of mRNAs may confer growth advantages. 247 
Finally, tumours are highly heterogeneous and the distinct tumour populations may be more 248 
or less sensitive to changes in m6A levels.  249 
 250 
RNA modifications regulating tumour invasion and metastasis 251 
Phenotypic transitions between cell states also occurs in cancer and include epithelial-to-252 
mesenchymal transition (EMT), cancer stem-like properties, metabolic reprogramming, the 253 
emergence of therapy resistance, and programmed cell death. RNA modifying enzymes are 254 
often required for cell survival in response to external stress stimuli (e.g. UV-radiation and 255 
oxidative stress) 103. Tumour cells are constantly exposed to a hostile microenvironment, due 256 
to shortage of oxygen and nutrients; and hypoxia-induced gene activity is crucial for tumour 257 
metastasis 104,105. Although hypoxia can dynamically change tRNA modifications 106, their 258 
precise functional roles during tumour cell invasion and metastasis is unclear.  259 
 260 
Several mcm5s2U writers are upregulated in cells undergoing EMT, and ELP3 promotes 261 
translation of LEF1 to sustain metastasis in invasive breast cancer mouse models 71. Cellular 262 
migration and invasion is impaired in the absence of NSUN2 in vitro 64,107,108 and tRNA-263 
derived cleavage products have been shown to modulate the metastatic potential of breast 264 
cancer cells 109.  265 
 266 
The m6A writer METTL3 enhances translation initiation of certain mRNAs including 267 
epidermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ, and thereby 268 
promotes growth, survival, and invasion of human lung cancer cells (Figure 3) 100. METTL3 269 
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has been also described to promote liver cancer progression through an YTHDF2-dependent 270 
mechanism and knockout of METTL3 suppressed tumorigenicity and lung metastasis in vivo 271 
110.   272 
 273 
Conversely, downregulation of METTL14 enhances metastasis in hepatocellular carcinoma 274 
(HCC) 111. Both METTL3 and METTL14 have been described to modulate the microRNA 275 
(miRNA)-guided RNA silencing pathway 111,112. METTL3 methylates pri-miRNA and marks 276 
them for recognition and processing by the microprocessor complex subunit DCR8 112. 277 
Similarly, METTL14 interacts with DGCR8 to enhance miR126 processing, a miRNA 278 
associated with invasive potential of HCC cell lines 111.  279 
 280 
RNA modifications regulating drug resistance 281 
Several recent studies demonstrated a link between RNA modifications and tumour cell 282 
survival in response to chemotherapeutic drug treatments. The coordinated modification of 283 
tRNAs by NSUN2 and METTL1, that mediates m7G methylation in tRNAs, was first 284 
implicated in mediating sensitivity of Hela cells towards the cytotoxic agent 5-Fluorouracil 285 
(5-FU) 64,113,114. 5-FU is commonly used to treat squamous cell carcinomas 115. Removal of 286 
NSUN2 in mouse cutaneous tumours increases the number of undifferentiated stem and 287 
progenitor cells; however, NSUN2-lacking tumour cells are also highly sensitive towards 288 
cytotoxic drug treatment with 5-FU and cisplatin 64. This finding highlights the importance of 289 
the dynamic deposition of m5C into RNA. While stem and tumour-initiating cells lack 290 
NSUN2 to maintain a low translating stem cell state 64,116, NSUN2 up-regulation, and thus 291 
methylation of the RNA, is required to activate the appropriate survival pathways to 292 
regenerate the tumour after cytotoxic insult (Figure 3) 64. The high sensitivity of the tumour 293 
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cells towards drug treatment is angiogenin-depended and is therefore at least in part regulated 294 
via tRF formation 64.  295 
 296 
Activation of the PI3K signaling pathway in melanoma cells enhances the expression of 297 
mcm5s2U writers 79. The tRNA wobble modification mcm5s2U is also required for specific 298 
codon decoding during translation and sustains resistance in melanoma 79. Rewiring of 299 
protein synthesis during BRAFV600E-driven resistance to targeted therapy induces a 300 
translational bias for mcm5s2U-dependent codons, which are for instance found in the Hif1a 301 
mRNA. The enhanced synthesis of the HIF1α protein thereby promotes glycolysis and 302 
maintains the metabolic requirements for the melanoma cells 79. The resistant cells are re-303 
sensitized to drug treatment through depletion of the mcm5s2U writers (Figure 3) 79. 304 
Together, these recent studies highlight the importance of RNA modification pathways in 305 
most aspects of tumourigenesis.  306 
 307 
Summary and future prospective 308 
RNA modifications are key players in regulating cell fate decision during development. More 309 
recently, RNA modifications also emerged as an important regulator of cancer. Similar to 310 
stem cells in most adult tissues, also tumour-initiating cells maintain the tumour in the long 311 
term. An important feature of tumour-initiating cells is to efficiently adapt self-renewal, 312 
proliferation and survival pathways to external cues. A dependency on RNA modifications to 313 
switch cell fates, for example from a proliferating tumour cells to a quiescent tumour-314 
initiating cell in response to chemotherapeutic drug treatment, may represent a window of 315 
opportunity to specifically target tumour-initating or resistant cell populations.  316 
 317 
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Cancer cells rapidly adapt to extreme environmental conditions by changes in specific 318 
metabolic pathways and through translational control, mediating an adaptive response to 319 
oncogenic stress conditions 41,117. RNA modifications emerged as one mechanistic link 320 
between metabolism and enhanced codon-dependent translation of HIF1α for instance to 321 
promote glycolytic metabolism 79. Similarly, RNA modifications promote gene-specific 322 
translation of one or several groups of tumour driver and suppressor genes. Thus, the 323 
modulation or inhibition of RNA modification pathways offer novel therapeutic strategies to 324 
target specific tumour populations, such as slow cycling tumour-initiating populations or 325 
resistant tumour cells.  326 
 327 
Depending on the tumour’s heterogeneity, distinct RNA modifications patterns may be used 328 
to identify tumour-initiating cells or to distinguish resistant from drug responsive tumour 329 
populations. However, whether this could be exploited as a novel biomarker is difficult to 330 
predict for several reasons. First, the tumour population of interest might be rather marked by 331 
the absence than the presence of distinct modifications. Second, current methods to detect 332 
RNA modifications suitable for easy, sensitive and reliable high throughput detection are 333 
currently not available. Third, aberrant expression of an RNA modifier is often required for 334 
the mis-expression of cell-type specific gene clusters. Thus, putative biomarkers may only be 335 
suitable for distinct subtypes of tumours.  336 
 337 
While aberrant expression of RNA modifying enzymes has now been described for most 338 
aspects of tumourigenesis, the precise contributions of the enzymes and respective 339 
modification to tumour initiation, growth, metastasis and resistance needs to be further 340 
investigated. Currently, it also remains unclear how specific modifications influence different 341 
tumour cell populations and how precisely they regulate survival, longevity and resistance. In 342 
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addition, the dynamic expression patterns of writer, reader and eraser proteins complicates 343 
the identification of the precise functional consequences of aberrant deposition of 344 
modifications on RNA metabolism and tumour cell fate decisions. Furthermore, with the 345 
exception of some tRNA modifications, it is currently largely unclear how different 346 
modifications influence each other and affect the binding to RNA-binding proteins. The 347 
development of new tools for the identification and quantification of RNA modification will 348 
be essential to further unearth their roles in the different steps of cancer development.  349 
  350 
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Figure Legends 682 
Figure 1: RNA modifications and their writer proteins. a, Schematic representation of a 683 
tRNA molecule and examples of RNA modifications and their modifying enzymes. 684 
Modifications at the wobble position are highlighted in purple. b, Schematic representation of 685 
the modifications internal to messenger RNA. Some of these modifications are enriched in 686 
the 5’UTR, the coding sequence or the 3’UTR of the mRNA. m6A is catalyzed by a complex 687 
of multi-proteins containing enzymes and accessory proteins. Abbreviations: m1A: N1-688 
methyladenosine; Ψ: pseudouridine; rT: ribothimidine; m5C: 5-methylcytosine; D: 689 
dihydrouridine; m7G, 7-methylguanosine; m1I: 1-methylinosine; i6A: N6-690 
isopentenyladenosine; m1G: 1-methylguanosine; yW: wybutosine; t6A: N6-691 
threonylcarbamoyladenosine; I: inosine; Gm: 2'-O-methylguanosine; Cm: 2'-O-692 
methylcytidine; mcm5U, 5-methoxycarbonylmethyluridine; mcm5s2U, 5-693 
methoxycarbonylmethyl-2-thiouridine; ncm5U: 5-carbamoylmethyluridine; ncm5Um: 5-694 
carbamoylmethyl-2'-O-methyluridine; s2U: 2-thiouridine; Am: 2'-O-methyladenosine; m2G: 695 
N2-methylguanosine; m6Am: N6,2'-O-dimethyladenosine; hm5C: 5-hydroxymethylcytidine. 696 
PUS: Pseudouridylate Synthase; TRUB2: TruB Pseudouridine Synthase Family Member 2; 697 
NSUN2, NOP2/Sun RNA methyltransferase family member 2; WDR4, WD repeat domain 4; 698 
DNMT2, DNA methyltransferase 2; TRM or TRMT, tRNA methyltransferase; ELP, 699 
Elongator protein homolog; CTU: Cytosolic Thiouridylase; ALKBH: AlkB Homolog 8, 700 
TRNA Methyltransferase; ADAT3, adenosine deaminase acting on tRNA 3; TET: Tet 701 
Methylcytosine Dioxygenase; DKC1: Dyskerin Pseudouridine Synthase 1; RBM: RNA 702 
Binding Motif Protein; ZC3H13: Zinc Finger CCCH-Type Containing 13; VIRMA: Vir Like 703 
m6A Methyltransferase Associated; WTAP: WT1 Associated Protein; METTL: 704 
Methyltransferase Like. 705 
 706 
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Figure 2: RNA modifications regulate gene expression programs. a, m6A is deposited by 707 
a ‘writer’ multi-protein complex (i.e. METTL3, METTL14) and removed by ‘eraser’ 708 
demethylases (i.e. FTO, ALKBH5), which induce stabilization or decay of the target mRNA. 709 
In the cytoplasm, the mRNA modifications are recognized by ‘reader’ proteins. b, The 710 
deposition of mcm5s2U modification is required for the optimal base pairing between 711 
tRNAUUU, tRNAUUC, tRNAUUG and tRNAUCU and the corresponding codons enriched in 712 
specific mRNA targets (i.e. Sox9, Dek, Lef1). c, tRNAs are methylated by NSUN2 in the 713 
nucleoli. The m5C modification reduces the affinity to the endonuclease angiogenin in the 714 
cytoplasm. m5C maintains global protein synthesis. Loss of m5C alters the biogenesis of 715 
tRNA-derived small non-coding RNA fragments (tRFs), which inhibit de novo protein 716 
synthesis.  717 
 718 
Figure 3: Roles of RNA modifications in cancer. RNA modifications are involved in 719 
multiple aspects of tumourigenesis. mcm5s2U is required for Wnt-driven colorectal cancer 720 
(CRC) initiation, development of lung metastasis from PyMT breast tumours, and PI3K 721 
pathway-addicted resistance to therapy in melanoma. m5C levels are high in committed 722 
progenitors of skin tumours, and it is crucial for resistance to drug treatment. Lack of NSUN2 723 
increases the number of undifferentiated stem and progenitor cells. Elevated levels of m6A on 724 
specific mRNA inhibit metastasis in hepatocellular carcinoma (HCC) and growth in 725 
glioblastoma tumours. m6A is also advantageous for the maintenance of a cell-726 
undifferentiated state in leukemia and promotes tumour initiation. In breast cancer cell lines, 727 
up-regulation of ALKBH5 enhances tumour initiation capacity. 728 
 729 
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